Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyproheptadine/Prazosin - Kinnov Therapeutics

Next Previous
X
Search
Drug Profile

Cyproheptadine/Prazosin - Kinnov Therapeutics

Alternative Names: Cyproheptadine+prazosin; KT 110; Periactine+Alpress

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Greenpharma SAS; Key-Obs
  • Developer Kinnov Therapeutics
  • Class Antihypertensives; Antimigraines; Dibenzocycloheptenes; Drug withdrawal therapies; Piperidines; Quinazolines; Sedating antihistamines
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Bradykinin receptor antagonists; Cholinergic receptor antagonists; Histamine H1 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alcoholism
  • Preclinical Cocaine-related disorders; Post-traumatic stress disorders
  • No development reported Substance-related disorders

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Substance-related disorders in France
  • 17 Jan 2024 Preclinical trials in Cocaine-related disorders in France (unspecified route) (Kinnov Therapeutic pipeline, January 2024)
  • 17 Jan 2024 Preclinical trials in Post-traumatic stress disorders in France (unspecified route) (Kinnov Therapeutic pipeline, January 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top